Michalis Papadakis, CEO & Co-Founder, Brainomix

Brainomix is an Oxford University spinout using artificial intelligence to improve diagnosis and treatment decisions in stroke and lung disease.

Founded on world-leading academic research, the company has developed technology that helps clinicians interpret medical imaging more quickly and accurately, supporting faster treatment decisions and better patient outcomes.

In the latest episode of Meet the Portfolio, CEO and Co-Founder Dr Michalis Papadakis discusses the origins of Brainomix, the clinical challenge that inspired its creation, and the journey from university spinout to international healthcare company.

The conversation explores how the team identified an unmet need within stroke care, how advances in AI are helping transform medical decision-making, and what it takes to build and scale a business based on cutting-edge science.

Watch the video to learn more about Brainomix’s story, its growth journey, and its experience as part of the Parkwalk portfolio.

To find out more about Brainomix, visit their website or our portfolio page here.

Access spinouts from the University of Oxford

Oxford Venture Fund

An early-stage investment fund backing technology spun out of the University of Oxford. These funds provide funding and support to companies founded on the University of Oxford’s research, helping transform these new scientific discoveries into tomorrow’s solutions.
Portfolio size
5+ companies
Stage
Seed-Series A
Tax reliefs
EIS tax reliefs available
Launch date
Coming soon
Find out more

The products shown on this website will place your capital at risk and investors may not get back the full amount invested. Past performance may not be repeated and is not indicative of future results.

Parkwalk funds invest in smaller and unquoted companies which carry a higher risk than many other forms of investment. There is no guarantee that target returns will be achieved. There is no liquid market for shares in unquoted companies and there can be difficulties, in valuing and disposing of investments in such companies. Tax reliefs will depend on the investors’ individual circumstance and are subject to change.

Parkwalk does not provide investment or tax advice, and the information on this website should not be construed as such. Parkwalk recommends investors seek advice from a regulated financial adviser that specialises in EIS fund investments before making an investment decision. An investment into any of the funds managed by Parkwalk may only be made on the basis of the information set out in the Information Memorandum and Key Information Document.

The information on this website is directed at United Kingdom residents only. Please confirm you have read this warning and are happy to proceed.